{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:48:48Z","timestamp":1782398928932,"version":"3.54.5"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse drug reactions still with controversy in treatment. Complete blood cell count-derived inflammatory biomarkers reflect systemic inflammation, and their value in SJS\/TEN has not been fully studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the therapeutic efficacy of corticosteroid combined with adalimumab (CA), corticosteroid combined with intravenous immunoglobulin (CI) and corticosteroid monotherapy (CM), and explore prognosticators on severity and prognosis of SJS\/TEN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All inpatients with SJS\/TEN treated with CA, CI or CM in two hospitals between 2015 and 2024 were studied. We calculated biomarkers, including the\u00a0neutrophil\/lymphocyte ratio (NLR), derived neutrophil\/(leucocyte minus neutrophil) ratio (dNLR), monocyte\/lymphocyte ratio (MLR), platelet\/lymphocyte ratio (PLR) and neutrophil\/(lymphocyte \u00d7 platelet) ratio (NLPR), and analysed their correlations with severity and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 136 patients, 29 patients were treated with CA, 18 patients were treated with CI and 89 patients were treated with CM. The mortality rate in the three groups was much lower than expected based on the\u00a0Severity of Illness Score for Toxic Epidermal Necrolysis (SCORTEN). The days to improvement of original lesions and days to no new lesions developing in CA and CI were significantly fewer than those in CM. NLR, dNLR, PLR and NLPR were independent risk factors for the elevation of the SCORTEN score, and MLR was an independent prognostic factor for healing time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The therapeutic efficacy of CA and CI is better than CM, and the incidence of complications is not increased. NLR, dNLR, PLR and NLPR may serve as potential prognosticators of severity in SJS\/TEN. Higher MLR appears to be a potential poor prognostic factor for healing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag088","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:40:11Z","timestamp":1771936811000},"page":"1263-1271","source":"Crossref","is-referenced-by-count":0,"title":["The effect of different therapies and complete blood cell count-derived inflammatory biomarkers on the prognosis of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis"],"prefix":"10.1093","volume":"51","author":[{"given":"Pei-Yu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Hang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Wen","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Friendship Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026062510020100500_llag088-B1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"2026062510020100500_llag088-B2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.burns.2019.10.008","article-title":"Retrospective study of 213 cases of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis from China","volume":"46","author":"Yang","year":"2020","journal-title":"Burns"},{"key":"2026062510020100500_llag088-B3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ijd.13379","article-title":"A retrospective analysis of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis treated with corticosteroids","volume":"55","author":"Liu","year":"2016","journal-title":"Int J Dermatol"},{"key":"2026062510020100500_llag088-B4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/1346-8138.13040","article-title":"Clinical profiles and treatment outcomes of systemic corticosteroids for toxic epidermal necrolysis: a retrospective study","volume":"43","author":"Choonhakarn","year":"2016","journal-title":"J Dermatol"},{"key":"2026062510020100500_llag088-B5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.iio.0000177430.89645.6d","article-title":"Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens\u2013Johnson syndrome","volume":"45","author":"Hynes","year":"2005","journal-title":"Int Ophthalmol Clin"},{"key":"2026062510020100500_llag088-B6","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2026062510020100500_llag088-B7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"2026062510020100500_llag088-B8","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s13555-023-00928-w","article-title":"Biologic TNF-\u03b1 inhibitors for Stevens\u2013Johnson syndrome, toxic epidermal necrolysis, and TEN\u2013SJS overlap: a study-level and patient-level meta-analysis","volume":"13","author":"Cao","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026062510020100500_llag088-B9","doi-asserted-by":"crossref","first-page":"1421684","DOI":"10.3389\/fimmu.2024.1421684","article-title":"Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study","volume":"15","author":"He","year":"2024","journal-title":"Front Immunol"},{"key":"2026062510020100500_llag088-B10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.anai.2022.05.009","article-title":"Etanercept treatment of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"129","author":"Tian","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026062510020100500_llag088-B11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026062510020100500_llag088-B12","doi-asserted-by":"crossref","first-page":"1188523","DOI":"10.3389\/fimmu.2023.1188523","article-title":"Case report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental adalimumab","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"2026062510020100500_llag088-B13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CCID.S401286","article-title":"Adalimumab for sintilimab-induced toxic epidermal necrolysis in a patient with metastatic gastric malignancy: a case report and literature review","volume":"16","author":"Zhang","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026062510020100500_llag088-B14","doi-asserted-by":"crossref","first-page":"1205687","DOI":"10.3389\/fimmu.2023.1205687","article-title":"Associations of complete blood cell count-derived inflammatory biomarkers with asthma and mortality in adults: a population-based study","volume":"14","author":"Ke","year":"2023","journal-title":"Front Immunol"},{"key":"2026062510020100500_llag088-B15","doi-asserted-by":"crossref","first-page":"20587384211048264","DOI":"10.1177\/20587384211048264","article-title":"Complete blood cell count-derived ratios can be useful biomarkers for neurological diseases","volume":"35","author":"Novellino","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2026062510020100500_llag088-B16","doi-asserted-by":"crossref","first-page":"1497068","DOI":"10.3389\/fimmu.2024.1497068","article-title":"Association between complete blood cell count-derived inflammatory biomarkers and gallstones prevalence in American adults under 60\u2005years of age","volume":"15","author":"Fu","year":"2025","journal-title":"Front Immunol"},{"key":"2026062510020100500_llag088-B17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens\u2013Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"2026062510020100500_llag088-B18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2026062510020100500_llag088-B19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"2026062510020100500_llag088-B20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2026062510020100500_llag088-B21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"2026062510020100500_llag088-B22","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaip.2020.09.048","article-title":"Detecting lesional granulysin levels for rapid diagnosis of cytotoxic T lymphocyte-mediated bullous skin disorders","volume":"9","author":"Chen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026062510020100500_llag088-B23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.7326\/0003-4819-151-7-200910060-00016","article-title":"Granulysin as a marker for early diagnosis of the Stevens\u2013Johnson syndrome","volume":"151","author":"Abe","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026062510020100500_llag088-B24","doi-asserted-by":"crossref","first-page":"1076029620950831","DOI":"10.1177\/1076029620950831","article-title":"The role of IL-13, IL-15 and granulysin in the pathogenesis of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"27","author":"Sadek","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026062510020100500_llag088-B25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/diagnostics15030290","article-title":"The potential roles of IL-1\u03b2, IL-6, and RIPK3 in the pathogenesis of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"15","author":"Sooranahalli","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"2026062510020100500_llag088-B26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis\u2013ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026062510020100500_llag088-B27","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1016\/j.jaip.2023.07.001","article-title":"Development and validation of a novel score to predict mortality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: CRISTEN","volume":"11","author":"Hama","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026062510020100500_llag088-B28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaad.2023.02.058","article-title":"APOA4 as a novel predictor of prognosis in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: a proteomics analysis from two prospective cohorts","volume":"89","author":"Gong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026062510020100500_llag088-B29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","article-title":"TNFalpha blockade in human diseases: mechanisms and future directions","volume":"126","author":"Wong","year":"2008","journal-title":"Clin Immunol"},{"key":"2026062510020100500_llag088-B30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/ajd.13911","article-title":"Highlighting adalimumab as a treatment option for systemic treatment of toxic epidermal necrolysis: a case series from a tertiary specialised burns centre","volume":"63","author":"Kherlopian","year":"2022","journal-title":"Australas J Dermatol"},{"key":"2026062510020100500_llag088-B31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"2026062510020100500_llag088-B32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000338202","article-title":"Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin","volume":"224","author":"Gaitanis","year":"2012","journal-title":"Dermatology"},{"key":"2026062510020100500_llag088-B33","first-page":"61","article-title":"Toxic epidermal necrolysis successfully treated with infliximab","volume":"23","author":"Z\u00e1rate-Correa","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2026062510020100500_llag088-B34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026062510020100500_llag088-B35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/09546634.2018.1509047","article-title":"A retrospective analysis of infections and antibiotic treatment in patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"31","author":"Diao","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2026062510020100500_llag088-B36","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2147\/CCID.S437936","article-title":"Association of complete blood cell count-derived inflammatory biomarkers with psoriasis and mortality","volume":"16","author":"Zhao","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026062510020100500_llag088-B37","doi-asserted-by":"crossref","first-page":"e70050","DOI":"10.1002\/iid3.70050","article-title":"Association between Systemic Immune-Inflammation Index and psoriasis, psoriasis comorbidities, and all-cause mortality: a study based on NHANES","volume":"12","author":"Zhao","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"2026062510020100500_llag088-B38","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3390\/jcm12062104","article-title":"Blood cells count derived inflammation indexes as predictors of early treatment response to dupilumab in patients with moderate-to-severe atopic dermatitis","volume":"12","author":"Zinellu","year":"2023","journal-title":"J Clin Med"},{"key":"2026062510020100500_llag088-B39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ced\/llae332","article-title":"Prognostic significance of the systemic immune-inflammation index in patients with Steven\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"50","author":"Han","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026062510020100500_llag088-B40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/CCID.S356450","article-title":"The correlation of neutrophil\u2013lymphocyte ratio and eosinophil count with SCORTEN in SJS\/TEN","volume":"15","author":"Primisawitri","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag088\/67118339\/llag088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/7\/1263\/67118339\/llag088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/7\/1263\/67118339\/llag088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:02:13Z","timestamp":1782396133000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/7\/1263\/8498156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag088","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,25]]}}}